Predictors of Significant Worsening of Patient-Reported Fatigue Over a 1-Month Timeframe in Ambulatory Patients With Common Solid Tumors

被引:14
|
作者
Fisch, Michael J. [1 ]
Zhao, Fengmin [2 ]
O'Mara, Ann M. [3 ]
Wang, Xin Shelley [5 ]
Cella, David [4 ]
Cleeland, Charles S. [5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] NCI, Bethesda, MD 20892 USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
cancer fatigue; symptom management; medical oncology; ambulatory care; CANCER-RELATED FATIGUE; CLINICALLY SIGNIFICANT FATIGUE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; BREAST-CANCER; ADJUVANT THERAPY; WOMEN; CHEMOTHERAPY; PREVALENCE;
D O I
10.1002/cncr.28437
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUNDUnderstanding the determinants of fatigue worsening may help distinguish between different fatigue phenotypes and inform clinical trial designs. METHODSPatients with invasive cancer of the breast, prostate, colon/rectum, or lung were enrolled from multiple sites. At enrollment during an outpatient visit and 4 or 5 weeks later, patients rated their symptoms on a numerical rating scale from zero to 10. A 2-point change on that scale was considered clinically significant for a change in fatigue. Effects of demographic and clinical factors on patient-reported fatigue were examined using logistic regression models. RESULTSIn total, 3123 patients were enrolled at baseline, and 3032 patients could be analyzed for fatigue change. At baseline, 23% of patients had no fatigue, 35% had mild fatigue, 25% had moderate fatigue, and 17% had severe fatigue. Key parameters in a model of fatigue worsening included fatigue at baseline (odds ratio [OR], 0.75), disease status (OR, 1.99), performance status (OR, 1.38), history of depression (OR, 1.28), patient perception of bother because of comorbidity (OR, 1.26), and treatment exposures, including recent cancer treatment (OR, 1.77) and receipt of corticosteroids (OR, 1.37). The impact of sex was examined only in patients with colorectal and lung cancer, and it was a significant factor, with men most likely to experience worsening of fatigue (OR, 1.46). CONCLUSIONSPredictors of fatigue worsening included multiple factors that were difficult to modify, including the baseline fatigue level, sex, disease status, performance status, recent cancer treatment, bother because of comorbidity, and history of depression. Future fatigue prevention and treatment trial designs should account for key predictors of worsening fatigue. Cancer 2014;120:442-450 (c) 2013 American Cancer Society.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 27 条
  • [1] PREDICTORS OF 1-MONTH AND 1-YEAR READMISSION FOR WORSENING OF HEART FAILURE IN AMBULATORY PATIENTS
    Alvarez-Garcia, Jesus
    Ferrero, Andreu
    Puig, Teresa
    Vazquez, Rafael
    Delgado, Juan
    Pascual Figal, Domingo
    Alonso-Pulpon, Luis
    Gonzalez Juanatey, Jose Ramon
    Rivera, Miguel
    Worner, Fernando
    Bardaji Ruiz, Alfredo
    Cinca, Juan
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A536 - A536
  • [2] Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors
    Fisch, Michael J.
    Zhao, Fengmin
    Manola, Judith
    Miller, Andrew H.
    Pirl, William F.
    Wagner, Lynne I.
    [J]. PSYCHO-ONCOLOGY, 2015, 24 (05) : 523 - 532
  • [3] Predictors of survival among PPCI patients at 1-month from Serdang PPCI STEMI network over 7 years
    Firdaus, M. L.
    Muizz, A. M. Abdul
    Kamaraj, S.
    Dalila, A. Siti
    Norfarahdina, R.
    Benjamin, L. T. X.
    Glendon, L. S. K.
    Ranga, A. R. Asri
    Abd Kahar, A. G.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 393
  • [4] PATIENT-REPORTED OUTCOMES IN THE GARNET TRIAL IN PATIENTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT SOLID TUMORS TREATED WITH DOSTARLIMAB
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Pennington, Kathryn
    Boklage, Susan
    Brown, Jubilee
    [J]. ONCOLOGY NURSING FORUM, 2022, 49 (02) : E57 - E58
  • [5] ASSOCIATION OF COMMON PATIENT-REPORTED IMMUNOTHERAPY SYMPTOMATIC SIDE EFFECTS AND PSEUDOPROGRESSION IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
    Vyas, Yamini
    Vera, Elizabeth
    Bryla, Christine
    Crandon, Sonja
    Wu, Jing
    Wall, Kathleen
    Theeler, Brett
    Siegel, Christine
    Reyes, Jennifer
    Penas-Prado, Marta
    Leggiero, Nicole
    Cordova, Christine
    Burton, Eric
    Antony, Ramya
    Boris, Lisa
    Aboud, Orwa
    Gilbert, Mark
    Armstrong, Terri
    [J]. NEURO-ONCOLOGY, 2019, 21 : 112 - 112
  • [6] The Role of the Mesopic Pupil on Patient-Reported Outcomes in Young Patients With Myopia 1 Month After Wavefront-Guided LASIK
    Schallhorn, Steven
    Brown, Mitch
    Venter, Jan
    Hettinger, Keith
    Hannan, Stephen
    [J]. JOURNAL OF REFRACTIVE SURGERY, 2014, 30 (03) : 159 - U91
  • [7] Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials
    Giesinger, Johannes M.
    Blazeby, Jane
    Aaronson, Neil K.
    Sprangers, Mirjam
    Fayers, Peter
    Sparano, Francesco
    Rees, Jonathan
    Anota, Amelie
    Wan, Chonghua
    Pezold, Mike
    Isharwal, Sumit
    Cottone, Francesco
    Efficace, Fabio
    [J]. VALUE IN HEALTH, 2020, 23 (05) : 666 - 673
  • [8] Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry
    Lala, Anuradha
    Shah, Palak
    Khalatbari, Shokoufeh
    Yosef, Matheos
    Mountis, Maria M.
    Robinson, Shawn W.
    Lanfear, David E.
    Estep, Jerry D.
    Jeffries, Neal
    Taddei-Peters, Wendy C.
    Stevenson, Lynne W.
    Richards, Blair
    Mann, Douglas L.
    Mancini, Donna M.
    Stewart, Garrick C.
    Aaronson, Keith D.
    [J]. JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : 765 - 774
  • [9] The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas
    Xiao Jun Wang
    Denise Yun Ting Goh
    Sreemanee Raaj Dorajoo
    Alexandre Chan
    [J]. Supportive Care in Cancer, 2017, 25 : 2815 - 2822
  • [10] Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy
    Dickson, Natalie R.
    Beauchamp, Karen D.
    Perry, Toni S.
    Roush, Ashley
    Goldschmidt, Deborah
    Edwards, Marie Louise
    Blakely, L. Johnetta
    [J]. JOURNAL OF PATIENT-REPORTED OUTCOMES, 2024, 8 (01)